Targeted therapy in prostate cancer.
The therapeutic approach to advanced prostate cancer has seen greater changes in the last 7 years than it did in the preceding 70. Although only one of the newly approved agents that improve overall survival is a targeted agent, it is a validation of the method of pathway analysis and drug design in delivering novel, clinically usable agents. As our knowledge of the molecular circuitry of tumour invasion, metastases and treatment resistance has become more refined, the number of new, potentially useful, targets has grown exponentially. This is reflected in the vast array of diverse targeted agents that are currently being evaluated in human trials. In this review, we briefly describe some of the key pathways that are involved in the evolution of the prostate cancer 'lethal phenotype', and review the clinical activity of some of the newly approved targeted therapies or those in advanced phases of clinical development.
Department of Surgery, University of Melbourne, Royal Melbourne Hospital, Parkville, Victoria, Australia. niallmcorcoran@gmail.com
Niall M
NM
Corcoran
Martin E
ME
Gleave
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D058990:Molecular Targeted Therapy; D011467:Prostate / Q000187:drug effects* / Q000473:pathology; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000473:pathology
D000970:Antineoplastic Agents